| Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells. | |
| | |
MedLine Citation:
|
PMID: 19345477 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Bispecific molecules (BSMs) facilitate the targeting of immune effector cells to tumor cells. Here we describe the construction and characterization of a recombinant BSM comprising two single chain fragments: H22(scFv), targeting the Fc gamma-receptor (CD64) on monocytes, and Ki4(scFv), targeting CD30 on Hodgkin lymphoma cells. A homologous, chemically-linked BSM has been described previously, but is heterogeneous and difficult to prepare. The recombinant version is easier to prepare and homogeneous, yet retains the antigen specificities and efficiently triggers CD64-related effector functions. The elimination of lymphoma cells was preferentially achieved by phagocytosis, not through the ADCC pathway additionally activated by the chemically-linked molecule. |
| | |
Authors:
|
Katharina Ranft; Theo Thepen; Rainer Fischer; Stefan Barth; Michael Stöcker |
Related Documents
:
|
3124997 - Antibody-dependent cell-mediated cytotoxicity against human eye muscle cells and orbita... 6405387 - Development of large granular lymphocytes with anomalous, nonspecific cytotoxicity in c... 1184117 - The effect of cytochalasin b on effector--target cell interaction. quantitative and ult... 3038737 - The cytotoxic response to murine cytomegalovirus: requirements for the generation of mc... 18259977 - Microbiological risk assessment in stem cell manipulation. 19336757 - Regulatory t-cell status in red cell alloimmunized responder and nonresponder mice. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-04-03 |
Journal Detail:
|
Title: Cancer letters Volume: 282 ISSN: 1872-7980 ISO Abbreviation: Cancer Lett. Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-07-14 Completed Date: 2009-07-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600053 Medline TA: Cancer Lett Country: Ireland |
Other Details:
|
Languages: eng Pagination: 187-94 Citation Subset: IM |
Affiliation:
|
Fraunhofer IME, Department of Pharmaceutical Product Development, Forckenbeckstr. 6, 52074 Aachen, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Bispecific
/
therapeutic use* Antibody-Dependent Cell Cytotoxicity Antigens, CD30 / analysis, immunology* Cell Line Cloning, Molecular Hodgkin Disease / immunology, therapy* Humans Immunoglobulin Fragments / therapeutic use* Phagocytosis Receptors, IgG / immunology* Recombinant Proteins / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Bispecific; 0/Antigens, CD30; 0/Immunoglobulin Fragments; 0/Receptors, IgG; 0/Recombinant Proteins; 0/immunoglobulin Fv |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
Next Document: Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) ...